Deirdre McMullen, MD
Family Medicine · Missouri City, TXNPI 1043206733
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.3%), speaking fees and education — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Life Technologies Corporation at 41.4% of the total. Reporting peaked in 2021 at $3,744 and has fallen 87.8% since, to $458 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $30.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Life Technologies Corporation$3K
- Novo Nordisk$546
- Lilly USA, LLC$438
- AbbVie$395
- Amgen$306
- AstraZeneca$261
- plus $2K from 42 others
Across 319 payments — averaging $7471.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$860K
- GSK$679K
- Novartis$204K
- Supernus Pharmaceuticals, Inc.$115K
- Endo Pharmaceuticals Inc.$112K
- AbbVie$75K
- plus $340K from 13 others
What the payments were for
- Speaking & faculty fees$3,00041%
- Food & beverage$4,22358%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,244 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $79,879 |
| MounjaroTirzepatide | 33 | $48,980 |
| NucyntaTapentadol Hcl | 11 | $31,448 |
| EliquisApixaban | 31 | $19,184 |
| FarxigaDapagliflozin Propanediol | 18 | $11,131 |
| LinzessLinaclotide | 14 | $7,406 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 128 | $4,202 |
| Levemir FlexpenInsulin Detemir | 12 | $2,672 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,509 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $1,537 |
| Levothyroxine Sodium | 153 | $1,498 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,189 |
| Potassium Chloride | 36 | $1,181 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $1,176 |
| Gabapentin | 74 | $1,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $546 | $79,87976 claims |
| Lilly USA, LLCMounjaro | $438 | $48,98033 claims |
| Collegium Pharmaceutical, Inc.Nucynta | $15 | $31,44811 claims |
| PfizerEliquis | $236 | $19,18431 claims |
| AstraZenecaFarxiga | $261 | $11,13118 claims |
| AbbVieLinzess, Synthroid | $395 | $8,32525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Missouri City
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.